UCB, a global biopharmaceutical company, is investing $5 billion to build a new biologics manufacturing facility in Gwinnett County, Georgia. This facility represents one of the largest investments ever made in Georgia, according to Governor Brian Kemp. The new plant will help UCB meet the growing demand for its medicines, including treatments for severe diseases, by strengthening its global production capabilities and ensuring a reliable supply of high-quality biologics, primarily for the U.S. market.
The facility will use cutting-edge technology, such as artificial intelligence (AI), robotics, and automation, to continuously produce complex biologics. This approach will improve efficiency and sustainability in manufacturing, which is crucial for delivering life-saving treatments to patients. UCB’s CEO, Jean-Christophe Tellier, emphasized that the investment will not only enhance their ability to develop and manufacture medicines but also create around 330 new high-quality jobs in Georgia. The state was chosen for its strong manufacturing tradition, skilled workforce, and long-standing presence of UCB’s U.S. headquarters.
This move is part of a broader trend in the pharmaceutical industry, with other companies also expanding their U.S. manufacturing operations. For example, Johnson & Johnson is investing $1 billion in cell therapy, AbbVie is spending $380 million to improve its active ingredient production, and Novartis is building a new facility in Texas to manufacture cancer therapies as part of a $23 billion U.S. investment plan over the next five years.
By strengthening its U.S. manufacturing network, UCB aims to ensure better access to essential medicines while supporting innovation and job growth in the region.